M&A Deal Summary

Momentum Biotechnologies Acquires OmicScouts

On March 5, 2025, Momentum Biotechnologies acquired life science company OmicScouts

Acquisition Highlights
  • This is Momentum Biotechnologies’ 1st transaction in the Life Science sector.
  • This is Momentum Biotechnologies’ 1st transaction in Germany.

M&A Deal Summary

Date 2025-03-05
Target OmicScouts
Sector Life Science
Buyer(s) Momentum Biotechnologies
Deal Type Add-on Acquisition

Target

OmicScouts

Freising, Germany
OmicScouts is a proteomics company focused on supporting drug and biomarker discovery through unique expertise and innovative technologies. By providing and developing system-wide assays to monitor protein activity and function in a physiological context, OmicScouts enables the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action, and drug response biomarkers. OmicScouts was founded in 2014 and is based in Freising, Germany.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Momentum Biotechnologies

Billerica, Massachusetts, United States

Category Company
Founded 2014
Sector Life Science
DESCRIPTION

Momentum Biotechnologies is a drug discovery partner providing specialized, cutting-edge mass spectrometry technologies to biopharmaceutical clients across the globe. Through a diverse array of services, including affinity-selection mass spectrometry (ASMS), covalent binding assays, chemoproteomics, and small-molecule analysis, Momentum helps clients identify, validate, and characterize therapeutic leads, accelerating critical drug discovery efforts. Momentum Biotechnologies was founded in 2014 and is based in Billerica, Massachusetts.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Germany M&A 1 of 1
Year: 2025 M&A 1 of 1